A new treatment approach – Eplerenone - in central serous chorioretinopathy - Case report • JML Journal of Medicine and Life

2016, Volume 9, Issue 1, pp 92 – 94

A new treatment approach – Eplerenone – in central serous chorioretinopathy – Case report

Issues

Special Issues

Authors and Affiliations

Cioboata M ^*

Alexandrescu C ^**

Hopinca CA ^*

Pienaru MC ^*

Merticariu A ^*

Schmitzer S ^*

* *Clinical Emergency Eye Hospital, Bucharest, Romania

** **Department of Ophthalmology, University Hospital, Bucharest

Correspondence to: Cioboată Miruna, MD, PhD, Clinical Emergency Eye Hospital, Bucharest, Alexandru Lahovari Square, Bucharest, Romania, Phone: +40213192751, E-mail: miruna.cioboata@yahoo.com

Abstract

We report the case of a 46-year-old patient, medical doctor with a relapsing unilateral CRSC-Central Serous Chorioretinopathy who was treated after an initial medical therapy (oral carbonic anhydrase inhibitor, oral antihistamines, non-steroidal anti-inflammatory drugs – systemic and topical), with an oral aldosterone antagonist-Eplerenone (Inspra), resulted in significant anatomic and visual improvements.

Abbreviations: CRSC = Central Serous Chorioretinopathy, R.E. = right eye, L.E. = left eye, BCVA = best corrected visual acuity, RPE = retinal pigment epithelium, OCT = optical coherence tomography, FDA = food and drug administration.

Keywords

central serous chorioretinopathyEplerenonemineralocorticoid receptors

Preview

JMedLife-09-92

Download PDF

About this article

PMC ID: 5052491
PubMed ID: 27713772
DOI:

Article Publishing Date (print): Jan-Mar 2016
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.